PharmaRoth Labs, Inc. (ROTH)

[old biohf guy]

FDA never banned Sucanon.
I will report when the yield sign is removed.

This is why investors own Roth. Metformin is the number one type 2 diabetes drug and yet is has significant side effects such as it’s hard on kidney function. Sucanon does not have this issue and yet has similar blood sugar reducing benefit - maybe a little less, but maybe a little more. Either way, the no side effect benefit would make Sucanon a clear winner.

The big two pieces of news everyone is waiting on is 1) the results of ABC hospital trials and 2) approval of India government. Either one of these would be worth .05 on share price in my opinion.


A quick comparison of Sucanon vs Metformin as to which reduces blood sugar more. This is pretty unscientific but it looks like results should be very similar based on a "head-to-head" competition.

Metformin:
http://www.diabetesnet.com/about-diabetes/diabetes-medications/metformin

The 3rd paragraph says:
Metformin lowers fasting blood glucose levels by an average of 25% (17 to 37%), postprandial blood glucose up to 44.5%, and the A1c by an average of 1.5% (0.8 to 3.1%).

Sucanon:
http://www.pharmaroth.com/clinical_summary.asp

Clinical studies have shown that Sucanon® reduces blood sugar readings by about 25% - 30% and brings high blood sugar back into the normal range (non-fasting blood sugar is above 200 mg/dL (milligrams per deciliter) or fasting blood sugar is above 126 mg/dL).

More test info: http://www.pharmaroth.com/clinical_results.asp


Looks like it should be a really close competition, but even if Sucanon comes in a little worse than Metformin, Sucanon has no negative side effects.